Amneal Reports Positive Phase 4 ELEVATE-PD Results for CREXONT
BRIDGEWATER, N.J., June 5, 2026 Amneal Pharmaceuticals announced positive interim results from the ongoing Phase 4 ELEVATE-PD study, demonstrating...
Amneal Pharmaceuticals
Advertisement
Amneal Accelerates Growth with Kashiv BioSciences Deal
Bridgewater, New Jersey, USA – April 22, 2026 In a transformative move within the global biopharmaceutical landscape, Amneal Pharmaceuticals...
Apiject Submits First-of-Its-Kind Prefilled Injection Device for FDA Review
STAMFORD, CT, September 25, 2025 — Apiject Systems, Corp., a leading medical technology innovator, submitted its New Drug Application...
Amneal Wins FDA Nod for Sodium Oxybate, Expanding Access to Narcolepsy Therapy
RIDGEWATER, N.J., September 11, 2025 – Amneal Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved its risperidone...
Advertisement
